She said, “I know Richard through Ian Malcolm. Ian and I are old friends.”
I see…” He continued to stare at her, as if he was unsure of her in some way.
She felt compelled to explain. “I’ve been in Africa. I decided to come here at the last minute,” she said. “Doc THorne called me.”
“Oh, of course. Doc.” The man nodded, and seemed to relax, as if everything now made sense to him.
She said, “Is Richard all right?”
“Well, I certainly hope so. Because we’re taking all this equipment to him.”
“You’re going to Sorna now?”
“We are, if this weather holds,” Dodgson said, glancing at the sky. “We should be ready to go in five or ten minutes. You know, you’re welcome to join us, if you need a ride,” he said cheerfully. “We could use the company. Where’s your stuff?”
“I’ve only got this,” she said, lifting her small backpack.
“Traveling light, eh? Well, good, Ms. Harding. Welcome to the party.”
He seemed entirely open and friendly now. It was such a marked change from his earlier behavior. But she noticed that the handsome man, King, remained distinctly uneasy. King turned his back to her, and acted very busy, shouting at the workmen to be careful with the last of the wooden crates, which were marked “Biosyn Corporation” in stenciled lettering. She had the impression he was avoiding looking at her. And she still hadn’t gotten a good look at the third man, on deck. It made her hesitate.
“You’re sure it’s all right….”
“Of course it’s all right! We’d be delighted!” Dodgson said. “Besides, how else are you going to get there? There’s no planes, the helicopter is gone.
“I know, I checked….”
“Well, then, you know. If you want to get to the island, you’d better go with us.”
She looked at the jeep on the boat, and said, “I think Doc must already be there, with his equipment.”
At the mention of that, the second man, King, snapped his head around in alarm. But Dodgson just nodded calmly and said, “Yes, I think so. He left last night, I believe.”
“That’s what he said to me.”
“Right.” Dodgson nodded. “So he’s already there. At least, I hope he is.”
From on deck, there were shouts in Spanish, and a captain in greasy overalls came and looked over the side. “Señor Dodgson, we are ready.”
“Good,” Dodgson said. “Excellent. Climb aboard, Ms. Harding. Let’s get going!”
King
Spewing black smoke, the fishing boat chugged out of the harbor, heading toward open sea. Howard King felt the rumble of the ship’s engines beneath his feet, heard the creak of the wood. He listened to the shouts of the crewmen in Spanish. King looked back at the little town of Puerto Cortés, a jumble of little houses clustered around the water’s edge. He hoped this damn boat was seaworthy – because they were out in the middle of nowhere.
And Dodgson was cutting corners. Taking chances again.
It was the situation King feared most.
Howard King had known Lewis Dodgson for almost ten years, ever since he had joined Biosyn as a young Berkeley Ph.D., a promising researcher with the energy to conquer the world. King had done his doctoral thesis on blood-coagulation factors. He had joined Biosyn at a time of intense interest in those factors, which seemed to hold the key to dissolving clots in patients with heart attacks. There was a race among biotech companies to develop a new drug that would save lives, and make a fortune as well.
Initially, King worked on a promising substance called Hemaggluttin V-5, or HGV-5. In early tests it dissolved platelet aggregation to an astonishing degree. King became the most promising young researcher at Biosyn. His picture was prominently featured in the annual report. He had his own lab, and an operating budget of nearly half a million dollars.
And then, without warning, the bottom fell out. In preliminary tests on human subjects, HGV-5 failed to dissolve clots in either myocardial infarctions or pulmonary embolisms. Worse, it produced severe side effects: gastrointestinal bleeding, skin rashes, neurological problems. After one patient died from convulsions, the company halted further testing. Within weeks, King lost his lab. A newly arrived Danish researcher took it over; he was developing an extract from the saliva of the Sumatran yellow leech, which showed more promise.